The effects of saperconazole on the morphology of Candida albicans, Pityrosporum ovale and Trichophyton rubrum in vitro

REFERENCES

• Barug D., de Groot C. Microscopic studies of Candida albicans and Torulopsis glabrata after in vitro treatment with bifonazole. Freeze fracture electron microscopy. Arzneimittel-Forschung Drug Research 1983; 33: 538–545
   PubMed Web of Science ®Google Scholar
• Barug D., Samson R.A., Kerkenaar A. Microscopic studies of Candida albicans and Torulopsis glabrata after in vitro treatment with bifonazole. Light and scanning electron microscopy. Arneimittel-Forschung Drug Research 1983; 33: 528–537
   PubMed Web of Science ®Google Scholar
• Borgers M. Changes in fungal ultrastructure after itraconazole treatment. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, R.A. Fromtling. J. R. Prous Science publishers, Barcelona 1987; 193–206, In
   Google Scholar
• Borgers M. Ultrastructural correlates of antimycotic treatment. Current Topics in Medical Mycology, M.R. McGinnis. Springer, New York 1988; 2: 1–39, In
   Google Scholar
• Borgers M., van Cutsem J. Oral Therapy in Dermatomycoses: A Step Forward. Ketoconazole induced morphological changes in yeasts and dermatophytes. Proceedings of a symposium, Frankfurt, 1985; 51–60, In
   Google Scholar
• Borgers M., vanden Bossche H., Brabander M. The mechanism of action of the new antimycotic ketoconazole. American Journal of Medicine 1983; 74: 2–7
   PubMedGoogle Scholar
• Borgers M., van De Ven M.-A. Degenerative changes in fungi after intraconazole treatment. Review of Infectious Diseases 1987; 9: S33–S42, Suppl. 1
   PubMedGoogle Scholar
• Borgers M., van De Ven M.-A., van Cutsem J. Structural degeneration of Aspergillus fumigatus after exposure to saperconazole. Journal of Medical and Veterinary Mycology 1989; 27: 381–389
   PubMedGoogle Scholar
• de Nollin S., Borgers M. The ultrastructure of Candida albicans after in vitro treatment with micronazole. Sabouraudia 1974; 12: 341–351
   PubMedGoogle Scholar
• de Nollin S., Borgers M. Scanning electron microscopy of Candida albicans after in vitro treatment with miconazole. Antimicrobial Agents and Chemotherapy 1975; 7: 704–711
   PubMed Web of Science ®Google Scholar
• de Nollin S., Borgers M. An ultrastructural and cytochemical study of Candida albicans after in vitro treatment with imidazoles. Mykosen 1976; 19: 317–328
   PubMedGoogle Scholar
• Faergemann J., Borgers M. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Dermato-Verereologica 1990; 70: 172–176
   PubMed Web of Science ®Google Scholar
• Garrison R.G. Ultrastructural cytology of pathogenic fungi. Fungi Pathogenic for Humans and Animals, D.H. Howard. Marcel Dekker, New York 1983; 229–321, In part A
   Google Scholar
• Gull K., Marriott M.S., Troke P.F. The effect of fluconazole on the morphology and ultrastructure of Candida albicans in vitro and in vivo. 1986, Abstract. 26th ICAAC, New Orleans, Sep. 29–Oct. 1
   Google Scholar
• Iwata K., Kanda Y., Yamaguchi H., Osumi M. Electron microscopic studies on the mechanisms of action of clotrimazole on Candida albicans. Sabouraudia 1973; 11: 205–209
   PubMedGoogle Scholar
• Jansen T., van De Ven M.-A., Borgers M., Odds F., van Gutsem J. Fungal morphology after treatment with saperconazole as a single oral dose in experimental vaginal candidosis in rats. Preclinical Research Report on R 66905 No. 31, Janssen Research Foundation, Beerse 1990
   Google Scholar
• Janssen Research Foundation. Saperconazole (R 66905) basic medical information brochure3rd edn. 1989
   Google Scholar
• Maillié M., Montés B., Lebecq J.C., Bastide J.-M. In vitro antifungal activity of saperconazole (R 66905) against Candida and Torulopsis. Mycoses 1989; 32: 631–637
   PubMed Web of Science ®Google Scholar
• Odds F.C. Morphogenesis in Candida, with special reference to C. albicans. Candida and Candidosis2nd edn, F.C. Odds. Ballière Tindall, London 1988; 42–59, In
   Google Scholar
• Odds F.C. Antifungal activity of saperconazole (R 66905) in vitro. Journal of Antimicrobial Chemotherapy 1989; 24: 533–537
   PubMed Web of Science ®Google Scholar
• Osumi M., Yamada N., Okada J., Yamaguchi H., Hiratani T., Plempel M. The effect of bifonazole on the structure of Trichophyton. Arzneimittel Forschung Drug Research 1983; 33: 1484–1491
   PubMed Web of Science ®Google Scholar
• Osumi M., Yamada N., Yamada Y., Yamaguchi H. The effect of bifonazole on the structure of Trichophyton mentagrophytes. Dermatologica 1984; 169: 19–32
   PubMedGoogle Scholar
• Preusser H.J. Die Wirkung van Econazol auf die Feinstruktur der Zellen von Trichophyton rubrum. Mykosen 1975; 18: 453–465
   PubMedGoogle Scholar
• Preusser H.J. Effects of in vitro treatment with econazole on the ultrastructure of Candida albicans. Mykosen 1976; 19: 304–316
   PubMedGoogle Scholar
• SAS Institute Inc. SAS/STAT user's guide4th edn. Cary, North Carolina 1989; 2: 1195–1210, (version 6)
   Google Scholar
• Scott E.M., Gorman S.P., McGrath S.J. Inhibition of hyphal development in Trichophyton mentagrophytes arthroconidia by ketoconazole and miconazole. Journal of Antimicrobial Chemotherapy 1985; 15: 405–415
   PubMed Web of Science ®Google Scholar
• Siegel S., Castellan N.J. Nonparametric Statistics for the Behavioral Sciences2nd edn. McGraw-Hill, New York 1988
   Google Scholar
• Troke P.F., Smith M.J. The in vitro and in vivo activity of fluconazole against Cryptococcus neoformans. Abstract, 27th ICAAC. New York Oct., 1987, 4–7
   Google Scholar
• van Cutsem J., Janssen P.A.J. Oral and parenteral treatment of invasive aspergillosis in non-predisposed and immunocompromised guinea-pigs with saperconazole (R 66905) and parenteral treatment with amphotericin B. Abstracts 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California October, 1988; 65–65, 1988
   Google Scholar
• van Cutsem J., van Gerven F., Janssen P.A.J. The in vitro and in vivo antidermatophyte activity of the new broad-spectrum antifungal triazole, saperconazole (R 66905). Proceedings of the 16th International Congress of Chemotherapy. Israël June, 1989; 535.1–535.2, 1989
   Google Scholar
• van Cutsem J., van Gerven F., Janssen P.A.J. Saperconazole, a new potent antifungal triazole: in vitro activity spectrum and therapeutic efficacy. Drugs of the Future 1989; 14: 1187–1209
   Google Scholar
• van Cutsem J., van Gerven F., van De Ven M.-A., Borgers M., Janssen P.A.J. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrobial Agents and Chemotherapy 1984; 26: 527–534
   PubMed Web of Science ®Google Scholar
• vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Current Topics in Medical Mycology, M.R. McGinnis. Springer, New York 1985; 1: 313–351, In
   Google Scholar
• vanden Bossche H. Importance and role of sterols in fungal membranes. Biochemistry of Cell Walls and Membranes in Fungi, P.J. Kuhn, A.P.J. Trinci, M.J. Jung, M.W. Goosey, L.G. Copping. Springer, Berlin 1990; 135–157, In
   Google Scholar
• vanden Bossche H., Marichal P., Willemsens G., Bellens D., Gorrens J., Roels L., Coene M.-C., Le Jeune L., Janssen P.A.J. Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycoses 1990; 33: 335–352
   PubMed Web of Science ®Google Scholar